TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells

被引：40

作者：

Zhang, Yaqin ^{[1
]}

Yoshida, Tatsushi ^{[1
]}

Zhang, Baolin ^{[1
]}

机构：

[1] US FDA, Div Therapeut Prot, Off Biotechnol Prod, Ctr Drug Evaluat & Res, Bethesda, MD 20014 USA

来源：

CANCER BIOLOGY & THERAPY | 2009年 / 8卷 / 10期

关键词：

TNF-related apoptosis inducing ligand (TRAIL); death receptor; endocytosis; apoptosis; caspases; cleavage; breast cancer cells; TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; MEDIATED ENDOCYTOSIS; LIGAND; INTERNALIZATION; APO2L/TRAIL; RESISTANCE; TRANSPORT; PROTEINS; THERAPY;

D O I：

10.4161/cbt.8.10.8141

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TNF-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent that selectively induces apoptosis in cancer cells over normal cells. Here, we show that TRAIL undergoes rapid endocytosis with its death receptors DR4, and likely DR5, in MDA-MB-231 human breast cancer cells. The internalized DR4, but not DR5, is cleaved in a caspase-dependent manner. Blockade of receptor internalization does not prevent caspase activation, but rather enhances apoptosis after TRAIL treatment. TRAIL-induced receptor endocytosis appears to undermine its ability in inducing apoptosis.

引用

收藏

页码：917 / 922

页数：6

相关论文

共 26 条

[1] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[2] Death-receptor activation halts clathrin-dependent endocytosis [J].

Austin, Cary D. ;

Lawrence, David A. ;

Peden, Andrew A. ;

Varfolomeev, Eugene E. ;

Totpal, Klara ;

De Maziere, Ann M. ;

Klumperman, Judith ;

Arnott, David ;

Pham, Victoria ;

Scheller, Richard H. ;

Ashkenazi, Avi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (27) :10283-10288

[3] Regulation of signal transduction by endocytosis [J].

Ceresa, BP ;

Schmid, SL .

CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (02) :204-210

[4] Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].

Chinnaiyan, AM ;

Prasad, U ;

Shankar, S ;

Hamstra, DA ;

Shanaiah, M ;

Chenevert, TL ;

Ross, BD ;

Rehemtulla, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759

[5] Tumor necrosis factor: Renaissance as a cancer therapeutic? [J].

Daniel, D. ;

Wilson, N. S. .

CURRENT CANCER DRUG TARGETS, 2008, 8 (02) :124-131

[6] TRAIL death receptors as tumor suppressors and drug targets [J].

Finnberg, Niklas ;

El-Deiry, Wafik S. .

CELL CYCLE, 2008, 7 (11) :1525-1528

[7] Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis [J].

Jin, ZY ;

McDonald, ER ;

Dicker, DT ;

El-Deiry, WS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (34) :35829-35839

[8] The TRAIL apoptotic pathway in cancer onset, progression and therapy [J].

Johnstone, Ricky W. ;

Frew, Ailsa J. ;

Smyth, Mark J. .

NATURE REVIEWS CANCER, 2008, 8 (10) :782-798

[9]

Keane MM, 1999, CANCER RES, V59, P734

[10] Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis [J].

Kohlhaas, Susan L. ;

Craxton, Andrew ;

Sun, Xiao-Ming ;

Pinkoski, Michael J. ;

Cohen, Gerald M. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (17) :12831-12841